Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Fluorinated HIV-1 protease inhibitors containing chiral hydroxyethylbenzene and indanol as P2′ ligands with potent activity against drug-resistant variants

European Journal of Medicinal Chemistry(2025)10.1016/j.ejmech.2025.118510Source: DataRank Database

Fluorinated HIV-1 protease inhibitors containing chiral hydroxyethylbenzene and indanol as P2′ ligands with potent activity against drug-resistant variants is a research paper published in European Journal of Medicinal Chemistry (2025). On theSindex it has a DataRank of 0. It has been cited 1 time.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access1 citations

Download PDF

Cite:

Linked data & code

pdb

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (9 grants)Impact (FWCI 0.73)OA: hybridTopics (30)IDs (PubMed, PMC, OpenAlex)Annotations (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (11)

E. Spielvogel ORCID,Desaboini Nageswara Rao ORCID,L.N. Rusere ORCID,Ala M. Shaqra ORCID,G.J. Lockbaum ORCID

Live enrichment

PubMed:41448052 PMC:PMC13091712 OpenAlex:https://openalex.org/W4417487832

Biological and Environmental Research

Grant: KP1605010

Brookhaven National Laboratory

Grant: DE-SC0012704

Argonne National Laboratory

Grant: DE-AC02-06CH11357

National Institute of General Medical Sciences

Grant: R01 GM135919

National Institute of General Medical Sciences

Grant: R35 GM151996

National Institute of General Medical Sciences

Grant: P30GM133893

Office of Science

National Institutes of Health

U.S. Department of Energy

FWCI

0.73

Citation Percentile

0.8%

Citation Trend

2026

hybridLicense: cc-by

journalhttps://doi.org/10.1016/j.ejmech.2025.118510

publisherhttps://doi.org/10.1016/j.ejmech.2025.118510

publisherhttps://api.elsevier.com/content/article/PII:S0223523425012759?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S0223523425012759?httpAccept=text/plain

repositoryhttps://pubmed.ncbi.nlm.nih.gov/41448052

Fields of Study

HIV/AIDS drug development and treatmentHIV Research and TreatmentHIV/AIDS Research and Interventions

MeSH Terms

Dose-Response Relationship, DrugHumansIndansLigandsMicrobial Sensitivity TestsStereoisomerismStructure-Activity RelationshipMolecular StructureHIV-1HIV ProteaseHIV Protease InhibitorsDrug Resistance, ViralHalogenation

Keywords

DarunavirMoietyProteaseCocrystalHydrogen bondPotencyMolecular modelStructure–activity relationshipDrug resistanceStructure-activity relationshipAntiviral ActivityX-ray StructureFluorinationHiv-1 Protease Inhibitors

Fluorinated HIV-1 protease inhibitors containing chiral hydroxyethylbenzene and indanol as P2′ ligands with potent activity against drug-resistant variants

FAIR Checklist

Authors (11)

Funding (9 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)